By Staff Reports
(DGIwire) — Being a teenager isn’t easy for anyone. Even the most popular kids in school have to deal with raging hormones and other biological realities of their growing and changing bodies. It sometimes seems miraculous that teens can come out on the other side of adolescence as fully functioning adults. For teenagers with eczema—the term for a group of medical conditions that cause the skin to become inflamed or irritated—it adds yet another layer of difficulty to deal with.
Acne is one affliction from which many teenagers suffer, and there are a wealth of products—both over-the-counter and prescription—to treat pimples. However, eczema is an entirely different story. According to the National Eczema Society, eczema—also known as atopic dermatitis—manifests itself in itchy, red rashes. It can appear all over the body, but most often appears on elbows and behind knees. And it is not limited to any specific age group. For example, babies can often have eczema on their face, especially the cheeks, chin, scalp, chest and outer arms. Although the spots where rashes occur are similar, each rash can be different for each person. It can look different each time, and range from mild to moderate to severe. People with eczema generally suffer from dry, sensitive skin, and the itch can be so bad that it can cause the person to scratch until their skin bleeds, which only makes the rash worse. This is called the itch-scratch cycle.
Doctors typically prescribe topical steroids to treat the symptoms of eczema. Unfortunately, while effective, long term use of topical steroids can lead to undesirable side effects, such as constriction of our blood vessels, rosacea, stretch marks, infections, and, although very rare, short stature.
Although there is currently no cure for eczema, it is manageable, and one company has dedicated its research to finding a treatment to break the itch-scratch cycle. Celsus Therapeutics is a New York and London-based drug development company focusing on anti-inflammatory, first-in-class synthetic drugs called Multi-Functional Anti-Inflammatory Drugs (MFAIDs). Celsus’s unique proprietary drug technology strives to offer an answer to the lack of satisfactory alternatives to corticosteroids in the treatment of a multitude of inflammatory diseases.
Gur Roshwalb, M.D., Chief Executive Officer of Celsus Therapeutics, says, “We believe MRX-6 might, if study results are positive, provide an effective and safe alternative to topical steroids, and we will work closely with global regulatory agencies to develop a new therapy for those suffering from eczema.”
The company’s lead drug candidate is called MRX-6, a topical cream formulated to treat eczema and its symptoms. Celsus recently received approval to conduct a Phase 2 study of MRX-6 in children.